Objective:
To discuss the procedure, documentation, coding, and coverage instructions for billing photobiomodulation (PBM) treatment for dry age-related macular degeneration (AMD), emphasizing the complexities involved.
Key Findings:
- PBM is FDA authorized and shows promise in improving vision for dry AMD patients, with treated patients demonstrating approximately 1 line improvement in mean visual acuity after 2 years.
Interpretation:
PBM represents a significant advancement in the treatment of dry AMD, potentially improving patient care, but practitioners must navigate complex billing and coverage landscapes.
Limitations:
- State laws may restrict who can perform PBM, with varying regulations impacting practice.
Conclusion:
PBM offers a new treatment option for dry AMD, but thorough research on state regulations and payer policies is crucial before implementation, with an emphasis on ongoing adaptation.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.